Tower Research Capital LLC (Trc) Fate Therapeutics Inc Transaction History

Tower Research Capital LLC (Trc)

$4.87 Billion
Q4 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 14,728 shares of FATE stock, worth $13,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,728

Previous 6,885 113.91%

Holding current value

$13,402

Previous $24,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$1.61 - $3.35 $12,627 - $26,274	7,843 Added 113.91%	14,728 $24,000
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $47,523 - $84,842	-15,232 Reduced 68.87%	6,885 $24,000
Q2 2024 Aug 13, 2024	BUY	$3.26 - $7.08 $45,366 - $98,525	13,916 Added 169.69%	22,117 $72,000
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $24,893 - $58,717	-7,032 Reduced 46.16%	8,201 $60,000
Q4 2023 Feb 13, 2024	SELL	$1.65 - $3.94 $42,228 - $100,836	-25,593 Reduced 62.69%	15,233 $56,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $32,356 - $80,730	16,018 Added 64.57%	40,826 $86,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $71,304 - $98,718	14,980 Added 152.42%	24,808 $118,000
Q1 2023 May 09, 2023	BUY	$4.24 - $11.12 $6,648 - $17,436	1,568 Added 18.98%	9,828 $56,000
Q4 2022 Feb 10, 2023	SELL	$9.86 - $23.83 $451,380 - $1.09 Million	-45,779 Reduced 84.71%	8,260 $83,000
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $981,579 - $1.68 Million	46,653 Added 631.64%	54,039 $1.21 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $89,824 - $214,154	-5,052 Reduced 40.62%	7,386 $183,000
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $251,957 - $511,897	8,492 Added 215.21%	12,438 $482,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $13,921 - $18,722	291 Added 7.96%	3,946 $231,000
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $24,478 - $39,536	413 Added 12.74%	3,655 $217,000
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $1.33 Million - $1.83 Million	-19,746 Reduced 85.9%	3,242 $281,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $1.14 Million - $1.85 Million	15,777 Added 218.79%	22,988 $1.9 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $167,100 - $442,867	4,387 Added 155.35%	7,211 $656,000
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $282,660 - $376,447	-9,295 Reduced 76.7%	2,824 $113,000
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $244,924 - $426,952	12,119 New	12,119 $416,000
Q4 2019 Feb 07, 2020	SELL	$13.39 - $20.73 $103,986 - $160,989	-7,766 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$15.47 - $22.5 $120,140 - $174,735	7,766 New	7,766 $121,000
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $420 - $598	-32 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $67,536 - $99,893	-5,883 Reduced 99.46%	32 $0
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $51,756 - $96,355	5,915 New	5,915 $96,000
Q2 2018 Aug 15, 2018	SELL	$9.16 - $13.48 $650 - $957	-71 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $447 - $977	71 New	71 $1,000
Q4 2017 Feb 09, 2018	SELL	$3.94 - $6.64 $38,154 - $64,301	-9,684 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $25,178 - $41,738	9,684	9,684 $39,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $88.3M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Fate Therapeutics Inc Transaction History